<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655378</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2020-1/TAT-01</org_study_id>
    <nct_id>NCT04655378</nct_id>
  </id_info>
  <brief_title>Validation of the IgA1 Detection Method With Gradient Glycosylation by Mass Spectrometry as a Potential Marker of Renal Involvement in Pediatric Rheumatoid Purpura</brief_title>
  <acronym>FOXIGA-2020</acronym>
  <official_title>Recherche d'un Marqueur Pronostique de l'Atteinte rénale du Purpura Rhumatoïde de l'Enfant. Validation de la méthode de détection Des IgA1 Avec Gradient de la Glycosylation Par spectrométrie de Masse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this ancillary study on the FoxTreg cohort, the study investigators will select variables&#xD;
      to input and thus develop two models (Linear Discriminant Analysis and Decision Tree). The&#xD;
      aim of this study is to validate the method in terms of repeatability, reproducibility,&#xD;
      control of pre-analytical conditions and sample conservation, to complete the screening of&#xD;
      IgA glycosylation in individuals of the FoxTreg cohort and to refine the glycopeptide&#xD;
      signature to predict renal involvement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycopeptide signature of serum from children with Rheumatoid Purpura</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry to identify the glycopeptides present and their level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repeatability of mass spectrometry in measuring glycopeptide signature</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry to identify the glycopeptides present and their level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of mass spectrometry in measuring glycopeptide signature</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry to identify the glycopeptides present and their level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of conservation of samples for measuring glycopeptide signature</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry to identify the glycopeptides present and their level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycopeptide signature of serum from all patients of the cohort</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry to identify the glycopeptides present and their level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between a normally glycosylated IgA and an IgA with GalNac polymer in Rheumatoid Purpura patients with / without renal impairment versus controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry to identify the glycopeptides present and their level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with IgA glycosylation abnormalities in Rheumatoid Purpura patient population with renal impairment polymer in Rheumatoid Purpura patients with / without renal impairment versus controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry of IgA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with IgA glycosylation abnormalities in Rheumatoid Purpura patient population with renal impairment polymer in Rheumatoid Purpura patients with / without renal impairment versus controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry of IgA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with IgA glycosylation abnormalities in each group</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry of IgA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with IgA glycosylation abnormalities in each group</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry of IgA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum immunoglobulin levels in patients with acute Rheumatoid Purpura and in remission</measure>
    <time_frame>Day 0</time_frame>
    <description>Mass spectrometry of immunoglobulins IgA, IgM and IgG (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of blood cell lines in patients with acute Rheumatoid Purpura and in remission.</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood cell lines, particularly Treg and Breg (number/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine levels in patients with acute Rheumatoid Purpura and in remission</measure>
    <time_frame>Day 0</time_frame>
    <description>pg/ml of TGF-β, IL-1, IL-6, TNF-α, IL-8, IL-10 and IL-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial Translocation in patients with Rheumatoid Purpura</measure>
    <time_frame>Day 0</time_frame>
    <description>Plasma levels of 16S rDNA (copies/µl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of LBP in patients with Rheumatoid Purpura</measure>
    <time_frame>Day 0</time_frame>
    <description>µg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of CD14s in patients with Rheumatoid Purpura</measure>
    <time_frame>Day 0</time_frame>
    <description>µg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial diversity in the gut microbiota in patients with Rheumatoid Purpura</measure>
    <time_frame>Day 0</time_frame>
    <description>Diversity Index</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">52</enrollment>
  <condition>Rheumatoid Purpura</condition>
  <condition>Pediatric ALL</condition>
  <arm_group>
    <arm_group_label>Acute Rheumatoid Purpura</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Purpura in Remission</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Without infection, inflammatory or auto-immune pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mass Sepctrometry</intervention_name>
    <description>Mass spectrometry (LC/MS) of purified immunoglobulins</description>
    <arm_group_label>Acute Rheumatoid Purpura</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Rheumatoid Purpura in Remission</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples already in existence&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is an ancillary study on the patient biobank of the FoxTreg study (NCT02317133). All&#xD;
        these patients had given their consent for blood sampling and the conservation of&#xD;
        biological samples within the Biological Resources Center (CRB) of Nîmes. A total of 97&#xD;
        patients were recruited, forming three groups:&#xD;
&#xD;
          -  Group A (n = 30): patients with active Rheumatoid Purpura according to the criteria of&#xD;
             EULAR / PRES / PRINTO 2010 [Ozen et al. 2010].&#xD;
&#xD;
          -  Group B (n = 30): patients in remission of Rheumatoid Purpura according to the&#xD;
             criteria of EULAR / PRES / PRINTO 2010 [Ozen et al. 2010].&#xD;
&#xD;
          -  Group C (n = 37): age-matched control subjects free of infectious / inflammatory /&#xD;
             autoimmune pathology.&#xD;
&#xD;
        For this &quot;FoxIgA-2020&quot; study, only sera collected from these patients not analyzed in the&#xD;
        &quot;FoxIgA&quot; study will be used.&#xD;
&#xD;
        Thus 52 samples will be analyzed for the FoxIgA-2020 study:&#xD;
&#xD;
          -  10 sera from group A&#xD;
&#xD;
          -  14 sera from group B&#xD;
&#xD;
          -  28 sera of group C&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient sera from biobank of the FoxTreg study (NCT02317133)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tu Anh TRAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nimes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010 May;69(5):798-806. doi: 10.1136/ard.2009.116657.</citation>
    <PMID>20413568</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura, Schoenlein-Henoch</mesh_term>
    <mesh_term>Purpura</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

